Pepgen reports fourth quarter and full year 2022 financial results and recent corporate developments

Boston, march 23, 2023 (globe newswire) -- pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results for the fourth quarter and full year ended december 31, 2022 and highlighted recent corporate developments.
PEPG Ratings Summary
PEPG Quant Ranking